[{"address1": "4503 Glencoe Avenue", "city": "Marina del Rey", "state": "CA", "zip": "90292", "country": "United States", "phone": "858 829 0829", "fax": "310 665 2963", "website": "https://www.armatapharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.", "fullTimeEmployees": 72, "companyOfficers": [{"maxAge": 1, "name": "Dr. Mina  Pastagia M.D., MS", "age": 48, "title": "Chief Medical Officer", "yearBorn": 1975, "fiscalYear": 2022, "totalPay": 537600, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Deborah L. Birx M.D.", "age": 66, "title": "CEO & Director", "yearBorn": 1957, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard  Rychlik", "age": 67, "title": "VP, Corporate Controller & Principal Financial Officer", "yearBorn": 1956, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bryan  Kadotani", "title": "Vice President of Program Management & Operations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Pierre  Kyme Ph.D.", "title": "Vice President of Business & Corporate Development", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.11, "open": 3.05, "dayLow": 3.05, "dayHigh": 3.36, "regularMarketPreviousClose": 3.11, "regularMarketOpen": 3.05, "regularMarketDayLow": 3.05, "regularMarketDayHigh": 3.36, "beta": 0.704, "forwardPE": -3.5227273, "volume": 13651, "regularMarketVolume": 13651, "averageVolume": 16278, "averageVolume10days": 35040, "averageDailyVolume10Day": 35040, "bidSize": 900, "askSize": 900, "marketCap": 112054456, "fiftyTwoWeekLow": 1.07, "fiftyTwoWeekHigh": 5.26, "priceToSalesTrailing12Months": 27.65411, "fiftyDayAverage": 2.4338, "twoHundredDayAverage": 2.1648, "currency": "USD", "enterpriseValue": 201725376, "floatShares": 10781800, "sharesOutstanding": 36146600, "sharesShort": 99062, "sharesShortPriorMonth": 98818, "sharesShortPreviousMonthDate": 1700006400, "dateShortInterest": 1702598400, "sharesPercentSharesOut": 0.0027, "heldPercentInsiders": 0.70155996, "heldPercentInstitutions": 0.03579, "shortRatio": 7.48, "shortPercentOfFloat": 0.0087, "impliedSharesOutstanding": 36146600, "bookValue": -0.343, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -59512000, "trailingEps": -1.65, "forwardEps": -0.88, "lastSplitFactor": "1:14", "lastSplitDate": 1557446400, "enterpriseToRevenue": 49.784, "enterpriseToEbitda": -4.955, "52WeekChange": 0.63684213, "SandP52WeekChange": 0.1985048, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "ARMP", "underlyingSymbol": "ARMP", "shortName": "Armata Pharmaceuticals, Inc.", "longName": "Armata Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 769440600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e9006f47-0d3e-3b07-8861-14c121fcb2a4", "messageBoardId": "finmb_84546611", "gmtOffSetMilliseconds": -18000000, "currentPrice": 3.1, "targetHighPrice": 9.0, "targetLowPrice": 7.0, "targetMeanPrice": 8.0, "targetMedianPrice": 8.0, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 23958000, "totalCashPerShare": 0.663, "ebitda": -40715000, "totalDebt": 113629000, "quickRatio": 1.483, "currentRatio": 1.672, "totalRevenue": 4052000, "revenuePerShare": 0.112, "returnOnAssets": -0.2531, "returnOnEquity": -3.58603, "grossProfits": -29509000, "freeCashflow": -30666376, "operatingCashflow": -49802000, "revenueGrowth": -0.084, "operatingMargins": -8.43755, "financialCurrency": "USD", "trailingPegRatio": null}]